A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Derivation and validation of an artificial intelligence-based plaque burden safety cut-off for long-term acute coronary syndrome from coronary computed tomography angiography




TekijätBar, Sarah; Knuuti, Juhani; Saraste, Antti; Klen, Riku; Kero, Tanja; Nabeta, Takeru; Bax, Jeroen J.; Danad, Ibrahim; Nurmohamed, Nick S.; Jukema, Ruurt A.; Knaapen, Paul; Maaniitty, Teemu

KustantajaOXFORD UNIV PRESS

KustannuspaikkaOXFORD

Julkaisuvuosi2025

JournalEHJ Cardiovascular Imaging / European Heart Journal - Cardiovascular Imaging

Tietokannassa oleva lehden nimiEUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING

Lehden akronyymiEUR HEART J-CARD IMG

Artikkelin numerojeaf121

Sivujen määrä11

ISSN2047-2404

eISSN2047-2412

DOIhttps://doi.org/10.1093/ehjci/jeaf121

Verkko-osoitehttps://doi.org/10.1093/ehjci/jeaf121

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/498482701


Tiivistelmä

Aims
Artificial intelligence (AI) has enabled accurate and fast plaque quantification from coronary computed tomography angiography (CCTA). However, AI detects any coronary plaque in up to 97% of patients. To avoid overdiagnosis, a plaque burden safety cut-off for future coronary events is needed.

Methods and results
Percent atheroma volume (PAV) was quantified with AI-guided quantitative computed tomography in a blinded fashion. Safety cut-off derivation was performed in the Turku CCTA registry (Finland), and pre-defined as ≥90% sensitivity for acute coronary syndrome (ACS). External validation was performed in the Amsterdam CCTA registry (the Netherlands). In the derivation cohort, 100/2271 (4.4%) patients experienced ACS (median follow-up 6.9 years). A threshold of PAV ≥ 2.6% was derived with 90.0% sensitivity and negative predictive value (NPV) of 99.0%. In the validation cohort 27/568 (4.8%) experienced ACS (median follow-up 6.7 years) with PAV ≥ 2.6% showing 92.6% sensitivity and 99.0% NPV for ACS. In the derivation cohort, 45.2% of patients had PAV < 2.6 vs. 4.3% with PAV 0% (no plaque) (P < 0.001) (validation cohort: 34.3% PAV < 2.6 vs. 2.6% PAV 0%; P < 0.001). Patients with PAV ≥ 2.6% had higher adjusted ACS rates in the derivation [Hazard ratio (HR) 4.65, 95% confidence interval (CI) 2.33–9.28, P < 0.001] and validation cohort (HR 7.31, 95% CI 1.62–33.08, P = 0.010), respectively.

Conclusion
This study suggests that PAV up to 2.6% quantified by AI is associated with low-ACS risk in two independent patient cohorts. This cut-off may be helpful for clinical application of AI-guided CCTA analysis, which detects any plaque in up to 96–97% of patients.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Julkaisussa olevat rahoitustiedot
The study was funded by the Finnish Foundation for Cardiovascular Research, Finnish State Research Funding (VTR 13403), and the Research Council of Finland. S.B. was supported by the Swiss National Science Foundation (P500PM_210788) and the Doctoral Programme for Clinical Research of the University of Turku, Finland. Cleerly Inc. performed AI-QCT analysis without costs.


Last updated on 2025-18-06 at 13:30